Takeda Pharmaceutical proposes $62bn acquisition of Shire to expand rare disease capabilities

Takeda Pharmaceutical proposes $62bn acquisition of Shire to expand rare disease capabilities

Takeda Pharmaceutical, a major Japanese pharmaceutical company, has made a $62 billion offer to acquire Shire, an Ireland-based leader in rare disease treatments. This proposal, Takeda’s fourth attempt to purchase Shire, comes after Shire had previously rejected three offers, citing undervaluation of its business and future growth prospects. Escalation in Acquisition Offers The latest bid […]

Takeda Pharmaceutical set to acquire TiGenix for €520m, enhancing gastroenterology and specialty care offerings

Takeda Pharmaceutical set to acquire TiGenix for €520m, enhancing gastroenterology and specialty care offerings

Japanese pharmaceutical giant Takeda Pharmaceutical has announced a proposal to acquire TiGenix, a Belgium-based cell therapy company, for €520 million. This acquisition is aimed at expanding Takeda’s late-stage gastroenterology portfolio and enhancing its presence in the American specialty care market. TiGenix, established in 2000, specializes in the development of novel treatments for serious medical conditions […]